20th Mar 2009 17:18
|
For immediate release |
20 March 2009 |
ABCAM PLC
("Abcam" or "the Company")
Director's Dealings
Cambridge UK, 20 March 2009: Abcam plc the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that on 19 March 2009 Peter Keen, a Non-Executive Director, sold 8,982 ordinary shares of 1p each in the Company ("Ordinary Shares") to a Self Invested Personal Pension Plan of which he is sole beneficiary, at a price of 612.25p per share.
Following this transaction Mr Keen's beneficial interest in the Company is unchanged at 8,982 Ordinary Shares, representing approximately 0.03% of the Company's issued share capital.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeffrey Iliffe, Chief Financial Officer www.abcam.com |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Mary-Jane Johnson / Stasa Filiplic |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 50,000 products, most of which are antibodies, from over 250 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs 225 staff in its three operating companies.
Related Shares:
ABC.L